Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emergent gets expedited review of anthrax drug
BioThrax is the only FDA approved product for pre-exposure prophylaxis of anthrax infection. The company is targeting a three dose regimen given two weeks apart for this indication.
BioThrax is the only FDA approved product for pre-exposure prophylaxis of anthrax infection. The company is targeting a three dose regimen given two weeks apart for this indication.
The trial was designed to evaluate the ability of FavId to induce humoral and cell-mediated immune responses, and to induce or maintain complete remission following autologous stem cell
The research and development efforts will initially target vaccines against influenza including both epidemic and pandemic forms of vaccine, with the opportunity to expand the collaboration to other
Ariad said the technology had already helped to facilitate the discovery of new product concepts, targets and tools. Ariad will have an equity stake in CellNexus and will
Boots will sell the impotence drug, made be Pfizer, in three of its Manchester stores from Valentine’s Day, for a trial period of six months. If the trial
Led by the National Cancer Research Institute and the University of Genoa in Italy, researchers pooled data from two studies comparing five year treatment with tamoxifen alone or
Under the terms of the agreement Guangdong Lantai Viewland Pharmaceutical will make a payment to Medivir by transferring equity. In addition Guangdong Lantai Viewland Pharmaceutical will pay royalties
The analysis of the trial showed it met its primary endpoint resulting in superior overall survival in those patients receiving Nexavar tablets versus those patients receiving placebo. It
The drug, TB-402, is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the blood. The study is a dose escalation
Lovenox is an anti-clot drug and Amphastar and Teva are seeking FDA permission to sell a copycat version of the drug. The loss of the patent also paves